Cardiovascular · Lipid RegulationRegulatory Approvalcommercialmid-term

FDA Accepts ANDA for Choline Fenofibrate by Macleods Pharmaceuticals

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Macleods Pharmaceuticals10 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/18/2026, 6:01:50 AM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the ANDA for Choline Fenofibrate signifies a potential shift in the competitive landscape of the lipid regulation market. Portfolio teams must evaluate the implications for market share and pricing strategies of existing fenofibrate products as competition intensifies. Regulatory context from FDA (FDA AP — FENOFIBRIC ACID (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new generic entry on market share and pricing strategies for branded fenofibrate products. The strongest clinical anchor is Hydrus® Microstent New Enrollment Post-Approval Study (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular · Lipid Regulation, 6 regulatory and 1 competitive items passed relevance filtering for Macleods Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This acceptance may increase competition in the lipid regulation market, particularly against existing fenofibrate products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FENOFIBRIC ACID (SUPPL) (FDA). Regulatory pathway relevance (nda). While the ANDA acceptance is a positive step, the timeline for final approval and subsequent market entry remains critical for assessing regulatory implications.

Key Risks

Elevated medium regulatory exposure for Macleods Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose) could weigh on Macleods Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The introduction of a generic competitor may lead to price erosion and affect the revenue of branded fenofibrate products, necessitating strategic adjustments.
Upside for Macleods Pharmaceuticals may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this new generic entry on market share and pricing strategies for branded fenofibrate products.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for final approval and market entry of Choline Fenofibrate.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FENOFIBRIC ACID (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROVOCHOLINE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROVOCHOLINE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUCCINYLCHOLINE CHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FENOFIBRIC ACID (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FENOFIBRIC ACID (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Modified Mini-PCNL Versus Standard PCNL for Complex Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Fitness, Cardiovascular and Brain Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Zexie decoction alleviates hyperlipidemia through modulation of the PPAR signaling pathway and lysophospholipid metabolism.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Macleods Pharmaceuticals

Commercial impact

medium

The introduction of a generic competitor may lead to price erosion and affect the revenue of branded fenofibrate products, necessitating strategic adjustments.

Regulatory impact

medium

While the ANDA acceptance is a positive step, the timeline for final approval and subsequent market entry remains critical for assessing regulatory implications.

What to watch

Monitor the timeline for final approval and market entry of Choline Fenofibrate.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.